Pomalidomide-C6-NH2

Background Introduction

Pomalidomide-C6-NH2 is a high-purity E3 ligase ligand-linker conjugate, designed specifically for PROTAC (Proteolysis Targeting Chimera) research and development. This compound incorporates pomalidomide, a potent cereblon (CRBN) E3 ubiquitin ligase ligand, tethered via a six-carbon (C6) alkyl linker to a terminal amine (NH2) group. The structural design allows for efficient coupling to target protein ligands, making it a versatile intermediate for custom PROTAC synthesis.

Mechanism

Pomalidomide-C6-NH2 acts as the E3 ligase recruiting component in PROTACs. Upon conjugation to a ligand that binds a protein of interest (POI), the resulting PROTAC molecule simultaneously binds to CRBN (an E3 ubiquitin ligase) via the pomalidomide moiety and to the POI through the user-attached ligand. This proximity induces ubiquitination of the target protein, triggering its subsequent degradation by the proteasome, thereby enabling selective and catalytic removal of disease-relevant proteins from cells.

Applications

Pomalidomide-C6-NH2 is widely used in PROTAC drug discovery for targeted protein degradation studies. Its primary application is as a building block for synthesizing bifunctional molecules that recruit CRBN to degrade various target proteins, such as kinases, transcription factors, and epigenetic modulators. This compound accelerates the development of novel therapeutics for cancers, neurodegenerative disorders, and immune diseases. Researchers also use Pomalidomide-C6-NH2 to explore structure-activity relationships (SAR) of PROTACs, optimize linker design, and develop custom protein degraders.

The Pomalidomide-C6-NH2 E3 Ligase Ligand-Linker Conjugate plays a crucial role in the development of PROTACs by facilitating targeted protein degradation. Its unique characteristics enhance the specificity and efficacy of PROTACs, making it a valuable tool for researchers exploring novel therapeutic strategies. The following provides a detailed description of this molecule.

Linker: This conjugate features a C6 alkyl linker, offering moderate length and flexibility, which is essential for optimal spatial orientation between the ligand and the target protein. Its non-cleavable nature ensures stable conjugation, maintaining the integrity of the PROTAC complex during cellular interactions.

Ligand: The ligand in this molecule is based on pomalidomide, a derivative of thalidomide known for its high binding affinity to the E3 ligase cereblon. Its structural characteristics enhance the recruitment of the ubiquitin-proteasome system, facilitating efficient protein degradation.

Reactive Site: The reactive site of Pomalidomide-C6-NH2 is the terminal amine group, which couples with target protein ligands through amide bond formation. This site is ideal for nucleophilic acyl substitution reactions, ensuring robust and stable linkage to a variety of target protein warheads.

Recommended Target Protein Ligand: The recommended warhead for this molecule is a small-molecule inhibitor with a carboxylic acid functional group, offering high specificity and binding affinity to the target protein. This configuration enables precise degradation of disease-related proteins, aiding in the elucidation of protein function and therapeutic mechanisms in experimental studies.